UCB Reports Sustained BIMZELX Responses in Psoriatic Arthritis
Atlanta, Georgia, United States, November 9, 2026 UCB, a global biopharmaceutical company, has announced additional Week 24 findings from...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Atlanta, Georgia, United States, November 9, 2026 UCB, a global biopharmaceutical company, has announced additional Week 24 findings from...
Berlin, Germany, November 10, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) has approved asundexian...
Ingelheim am Rhein, Germany, November 9, 2026 Boehringer Ingelheim has announced positive results from its global Phase III SYNCHRONIZE-CVOT...
Rahway, New Jersey, United States, November 9, 2026 Merck & Co., Inc. has announced positive results from its Phase...
Lyon, France, November 10, 2026 Valneva SE, a specialty vaccine company, has announced positive five-year antibody persistence results for...
New York, United States, November 9, 2026 Actinium Pharmaceuticals, Inc. has announced the formation of a new Scientific Advisory...
Boston, Massachusetts, United States, November 9, 2026 Aisa Pharma, Inc. has announced additional clinical findings from its Phase II...
Irving, Texas, United States, November 9, 2026 Caris Life Sciences has announced the publication of a new study highlighting...
Rockville, Maryland, United States, November 9, 2026 AbelZeta Inc. has announced updated clinical results from its first-in-human Phase I...
Indianapolis, Indiana, United States, November 9, 2026 Eli Lilly and Company has announced positive results from its Phase III...
